Tempus AI, Inc. $TEM Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. reduced its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 52.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,562 shares of the company’s stock after selling 177,679 shares during the quarter. Vestmark Advisory Solutions Inc. owned about 0.09% of Tempus AI worth $12,972,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at about $54,020,000. Geode Capital Management LLC boosted its position in shares of Tempus AI by 411.4% in the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after purchasing an additional 522,443 shares during the period. Marex Group plc purchased a new position in Tempus AI during the 2nd quarter worth approximately $26,620,000. Finally, Gilder Gagnon Howe & Co. LLC increased its position in Tempus AI by 1,747.6% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock worth $26,247,000 after buying an additional 390,723 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Stock Down 2.7%

TEM stock opened at $58.37 on Friday. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. The company has a fifty day moving average of $62.35 and a 200-day moving average of $73.50. The stock has a market capitalization of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22.

Insiders Place Their Bets

In other news, CFO James William Rogers sold 19,966 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the transaction, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. This represents a 15.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrew Polovin sold 12,874 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $75.00, for a total value of $965,550.00. Following the completion of the sale, the executive vice president directly owned 107,590 shares of the company’s stock, valued at $8,069,250. This represents a 10.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 775,159 shares of company stock worth $50,789,800. Company insiders own 26.27% of the company’s stock.

Analyst Upgrades and Downgrades

TEM has been the subject of several research analyst reports. BTIG Research increased their price objective on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Robert W. Baird assumed coverage on shares of Tempus AI in a research note on Tuesday. They issued an “outperform” rating and a $59.00 price objective on the stock. Piper Sandler reduced their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Canaccord Genuity Group lowered their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus target price of $85.92.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.